Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
Status:
Withdrawn
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the efficacy and safety of combination therapy with
ramucirumab, paclitaxel, and trastuzumab biosimilar as second line treatment of HER2 positive
metastatic gastric cancer after failure of first line chemotherapy including trastuzumab.
This study is a phase II, single-arm, open label, multi-center study.